Somatic p.T771R KDR (VEGFR2) mutation arising in a sporadic angioma during ramucirumab therapy

JAMA Dermatology

Volumn 151, Issue 11, 2015, Pages 1240-1243

  Lim, Young H ^a   Odell, Ian D ^a   Ko, Christine J ^a   Choate, Keith A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RAMUCIRUMAB; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ADULT; ANGIOMA; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; DRUG WITHDRAWAL; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEG DISEASE; LIVER METASTASIS; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUROPATHY; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECTUM CARCINOMA; SEQUENCE ANALYSIS; SOMATIC MUTATION; SPORADIC ANGIOMA; TELANGIECTASIA; VASCULAR LESION; VEGFR2 GENE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; GENETICS; HEMANGIOMA; MUTATION; PATHOLOGY; RECTAL NEOPLASMS; SKIN TUMOR;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; HEMANGIOMA; HUMANS; MALE; MUTATION; RECTAL NEOPLASMS; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84946866523     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.1925     Document Type: Article

References (16)

1. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011; 34(12):1785-1788.
2. Ferrara N, Hillan KJ, Gerber HP, NovotnyW. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400.
3. Hoeben A, Landuyt B, Highley MS,Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549-580.
4. Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014;2(12):123.
5. Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 1998;17(2):155-161.
6. O'Dwyer P, Benson AB, Hochster HS. A randomized phase II study of irinotecan and cetuximab with or without the anti-angiogenic antibody, ramucirumab (IMC-1121B), in advanced, K-ras wild-type colorectal cancer following progression on bevacizumab-containing chemotherapy. https://clinicaltrials.gov/ct2/show /NCT01079780. Accessed August 7, 2015.
7. Sathirapongsasuti JF, Lee H, Horst BA, et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics. 2011;27(19):2648-2654.
8. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3):207-215.
9. Pui CH, Behm FG, Raimondi SC, et al. Secondary acutemyeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989;321 (3):136-142.
10. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627.
11. Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol. 2013;4(3):253-263.
12. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69(18):7175-7179.
13. Vinod R, Ali SM, Ramesh N, et al. Targeted next generation sequencing of sarcomas for identification of therapeutic targets. Paper presented at: 2013 ASCO Annual Meeting; May 31 to June 4, 2013; Chicago, IL. Abstract 10577.
14. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426-433.
15. Boye E, JinninM, Olsen BR. Infantile hemangioma: challenges, new insights, and therapeutic promise. J Craniofac Surg. 2009;20 (suppl 1):678-684.
16. JengMR, Fuh B, Blatt J, et al. Malignant transformation of infantile hemangioma to angiosarcoma: response to chemotherapy with bevacizumab. Pediatr Blood Cancer. 2014;61(11): 2115-2117.